Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. in vitro-in vivo correlation with fluconazole

Drug Metabolism and Disposition

Volumn 36, Issue 7, 2008, Pages 1261-1266

  Lu, Chuang ^a   Berg, Cicely ^a   Prakash, Shimoga R ^a   Lee, Frank W ^a   Balani, Suresh K ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUCONAZOLE; MIDAZOLAM; OMEPRAZOLE; PHENYTOIN; RAPAMYCIN; TACROLIMUS; THEOPHYLLINE; TOLBUTAMIDE; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; CELL SUSPENSION; CONTROLLED STUDY; DRUG CROSS REACTIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; PHENOTYPE; PLASMA; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; FLUCONAZOLE; HEPATOCYTES; HUMANS;

EID: 46449093909     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019000     Document Type: Article

References (39)

1. Balani SK, Negaraja NV, Qian MG, Costa AO, Daniels JS, Yang H, Shimoga PR, Wu JT, Gan LS, Lee FW, et al. (2006) Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drag Metab Dispos 34:384-388.
2. Balant L (1981) Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet 6:215-241.
3. Bourri é M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
4. Crespi C (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235.
5. Debruyne D (1997) Clinical pharrnacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 33:52-77.
6. Galetin A, Burt H, Gibbons L, and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175.
7. Gelboin H, Krausz K, Gonzalez F, and Yang T (1999) Inhibitory monoclonal antibodies to human cvtochrome P450 enzymes: a new avenue for drag discovery. Trends Pharmacol Sci 20:432-438.
8. Gibbs MA, Kunze KL, Howald WH, and Thummel KE (1999) Effect of inhibition on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 27:596-599.
9. Hardman JG, Limbird LE, and Oilman AG, eds (2001) Goodman & Oilman's The Pharmacological Basis of Therapeutics, New York, McGraw-Hill.
10. Ito K, Brown H, and Houston JB (2004) Database analyses for prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
11. Ito K. Hallifax D, Ohach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844.
12. Kodawara T, Yono I, Masuda S, Ito T, Wakasugi H, Futami T, Hashimoto Y, Saito H, and Inui K (2001) Interaction of azole antifungal agent with human P-g]ycoprotein expressed in a kidney epithelial cell line LLC-PK1. Yakubutsu Dotai 16:5-11.
13. Lazar J and Wilner K (1990) Drug interactions with fluconazole. Rev Infec Dis 1990 (suppl 3):S327-S333.
14. Li AP, Lu C, Brent JA, Pharn C, Fackett A, Ruegg CE, and Silber PM (1999) Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 121:17-35.
15. Liu XR, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, and Brouwer KLR (1999) Biliary excretion in primary rat hepatocytes culture in a collagen-sandwich configuration. Am J Physiol 277:G12-G21.
16. Lu C, Berg C, Lee FW and Balani SK (2008) Prediction of pharmacokinetie drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug Metab Dispos 36:1255-1260.
17. Lu C and Li AP (2001) Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 134:271-281.
18. Lu C, Miwa GT, Prakash SR, Gan LS, and Balani SK (2007) A novel model for the prediction of drug-drug interactions in humans based on in vitro CYP phenotyping. Drug Metab Dispos 35:79-85.
19. Lu A, Wang R, and Lin J (2003) Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31:345-350.
20. Madan A, Dehaan R, Mudra D, Carrol K, Lecluyse E, and Parkinson A (1999) Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured hepatocytes. Drug Metab Dispos 27:327-335.
21. Newton DJ, Wang RW, and Lu A (1995) Cytochrome P450 inhibitors - evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
22. Niwa T, Inoue-Yamamoto S, Shiraga T, and Takagi A (2005b) Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull 28:1813-1816.
23. Niwa T, Shiraga T, and Takagi A (2005a) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28: 1805-1808.
24. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
25. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, and Wingard JR (1996) Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 61:1268-12726.
26. Rosemary L, Surendiran A, Rajan S, Shashindran CH, and Adithan C (2006) Influence of the CYP2C9 and CYP2C19 polymorphisms on phenytoin hydrolalion in healthy individuals from south India. Indian J Med Res 123:665-670.
27. Rostami-Hodjegan A, and Tucker GT (2004) "In silico" simulation to assess the "in vivo" consequences of "in vitro" metabolic drug-drug interactions. Drug Discov Today Technol 1:441-448.
28. Segel HS (1974) Enzyme Kinetics, New York, John Wiley & Sons.
29. Sewell RB, Brook CW, Mihaly GW, Morgan DJ, and Smallwood RA (1994) Intracellular binding is an important determinant of the avid hepatic uptake of the high clearance drug omeprazole. Biochem Pharmacol 48:846-849.
30. Shitara Y, Li AP, Keto Y, Lu C, Ito K, Itoh T, and Sugiyama Y (2003) Function of uptake transporters for taurocholate and estradiol 17β-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18:33-41.
31. Shou M, Lu T, Krausz K, Sai Y, Yang T, Korzekwa K, Gonzalez F, and Gelboin H (2000) Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol 394:199-209.
32. Soars MG, Gelboin HV, Krausz KW, and Riley RJ (2003) A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. Br J Clin Pharmacol 55:175-181.
33. Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JCL, et al. (2004) Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105-112.
34. Trapnell CB, Klecker RW, Jamis-Dow C, and Collins JM (1998) Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetie interactions with atovaquone, fluconazole, and valproic acid. Antimicrob Agents Chemother 42:1592-1596.
35. Uchaipichat V, Winner LK, Mackenzie PL, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
36. Uttamsingh V, Lu C, Miwa G, and Gan LS (2005) Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 33:1723-1728.
37. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001) Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 297:326-337.
38. Walsky RL and Obach RS (2003) Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metab Dispos 31:343.
39. Xia CQ, Liu N, Yang D, Miwa G, and Gan LS (2005) Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 33: 637-643.